Ir para o conteúdo principal

Aft Pharmaceuticals (ASX: AFP) — Perfil da empresa, notícias e dados financeiros

Logo de Aft Pharmaceuticals
AFP Aft Pharmaceuticals
Aft Pharmaceuticals primary media
Perfil da empresa

Aft Pharmaceuticals

Aft Pharmaceuticals is a New Zealand-based pharmaceutical company that develops, licenses, and commercializes proprietary and over-the-counter healthcare products globally. Founded in 1997, the company focuses on delivering therapeutic formulations across key categories including pain management, eyecare, dermatology, cold and flu, and prescription medicines. Its flagship patented pain relief formulation, Maxigesic, is distributed across multiple international markets. Aft Pharmaceuticals operates distribution networks across Australasia, Asia-Pacific, North America, Europe, and Africa, partnering with healthcare providers, retail pharmacies, and clinical networks to deliver prescription and non-prescription treatments.

Resumo

Public AUParticipação acionária
1997Ano de fundação
51–200Funcionários
Auckland, New ZealandSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Aft Pharmaceuticals

  • Patented Pain Management: Formulation and global distribution of patented dual-action pain relief products combining paracetamol and ibuprofen. Available in oral tablets, intravenous, liquid, and hot drink formats across international pharmaceutical markets in Australasia, Europe, the Americas, and Asia.
  • Over-the-Counter Healthcare: Non-prescription consumer health products covering pain relief, allergy care, cold and flu remedies, and gastrointestinal treatments. Distributed through retail pharmacy channels, supermarkets, and online platforms across New Zealand, Australia, and select export markets.
  • Prescription Pharmaceuticals: Development and marketing of branded and generic prescription medications across diverse therapeutic categories, including cardiovascular health, pain management, dermatology, oncology, and central nervous system disorders supplied directly to healthcare professionals and hospital pharmacy networks.
  • Hospital and Critical Care Products: Specialized injectable pharmaceuticals, critical care medications, and hospital-grade therapies supplied to public health authorities and private clinical facilities across Australasian markets, supporting inpatient surgical, emergency, and specialized therapeutic treatment regimens.
  • Ophthalmic and Eyecare Range: Specialized eye care treatments including preservative-free lubricating drops, dry eye therapies, and anti-inflammatory ophthalmic formulations distributed to eye clinics, optometrists, and retail pharmacies across regional and international distribution networks.
  • Dermatology and Skincare Therapies: Topical dermatological treatments, antibacterial creams, and specialized skin care products designed for infection management and wound care, distributed through community pharmacies, medical practices, and healthcare distribution channels across global markets.

equipe executiva do Aft Pharmaceuticals

  • Hartley AtkinsonCo-Founder, CEO, MD & Executive Director
  • Marree AtkinsonCo-Founder, Chief of Staff & Executive Director
  • Stuart D. HoulistonChief Financial Officer
  • Ioana StanescuChief Scientific Officer
  • Murray KeithGroup Marketing Manager

Comunicados recentes

O que a Aft Pharmaceuticals (AFP) comunicou ao mercado, do mais recente para o mais antigo.

  1. AFT 1H27 financial results and conference call
  2. AFT reports double digit growth in 1H FY27 and R&D progress
  3. Application for quotation of securities - AFP
  4. Capital Change Notice

Histórico de dividendos

Dividendos por ação pagos pela Aft Pharmaceuticals, por ano fiscal.

Dividendos por ação da Aft Pharmaceuticals por ano fiscal
Ano fiscalIntermediárioFinalEspecialTotal
FY2026—NZ$0.0162—NZ$0.0162
FY2025—NZ$0.0111—NZ$0.0111
FY2024—NZ$0.0098—NZ$0.0098
FY2023—NZ$0.0069—NZ$0.0069

Principais indicadores financeiros

Resultados divulgados pela Aft Pharmaceuticals, em NZD.

Cap. de mercado
373,4 mi
Receita (TTM)
254,7 mi
P/L
29.7
LPA (diluído, TTM)
0.1
Dividend yield
0.7%
Margem de lucro
5.8%
Receita e lucro anuais da Aft Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
256,6 mi25 mi14,8 mi
205,5 mi11,7 mi12 mi
194 mi20,3 mi15,6 mi
156,6 mi19,7 mi10,7 mi